convEyXO — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ConvEyXO is a pre-clinical stage biotech developing a scalable platform for RNA-enhanced exosome therapeutics aimed at degenerative diseases. The company's core technology involves proprietary methods for producing, purifying, and loading exosomes derived from an immortalized mesenchymal stem cell line, aiming for potency, consistency, and dramatically lower manufacturing costs. With a focus on extending healthspan by addressing inflammatory and age-related conditions, ConvEyXO is building a pipeline targeting musculoskeletal and metabolic degenerative diseases. The company is privately held, pre-revenue, and founded by experts in cell therapy and advanced manufacturing.

Degenerative DiseasesInflammatory Diseases

Technology Platform

Proprietary platform for RNA-enhanced exosome therapeutics. Includes an immortalized MSC cell line for consistent exosome production (iMSC 2.0), a scalable manufacturing/harvesting system (Exo-Harvest), a microfluidic mechanoporation technology for loading RNA cargo, and a bioinformatics tool (XomeXBio) for cargo optimization.

Opportunities

The global rise in age-related degenerative diseases creates a vast and growing market for disease-modifying therapies.

ConvEyXO's focus on scalable, affordable manufacturing positions it to address both clinical need and healthcare economic pressures, potentially enabling broad patient access and attractive commercial margins.

Risk Factors

The company faces significant scientific risk in proving the efficacy and safety of its novel RNA-exosome complexes, and regulatory risk as pathways for exosome therapies are still evolving.

As a pre-revenue, pre-clinical company, it is also highly dependent on securing ongoing funding to advance its programs.

Competitive Landscape

The exosome therapeutic space is competitive and rapidly evolving, with numerous biotechs and academic groups exploring exosomes for drug delivery and as therapeutics. ConvEyXO differentiates itself through its integrated platform claiming superior consistency, scalable low-cost manufacturing, and a proprietary RNA-loading technology designed to preserve exosome integrity.

More companies in Drug Delivery & Formulation →More companies in Belgium →